Information Provided By: 
Fly News Breaks for April 29, 2019
SILK
Apr 29, 2019 | 06:20 EDT
Stifel analyst Rick Wise started Silk Road Medical with a Buy rating and $44 price target. The company is in the early stages of commercializing an "innovative" suite of products that enable an entirely new, minimally-invasive procedure for the treatment of carotid artery disease, Wise tells investors in a research note. He believes the company's TCAR is poised to become standard of care in this "multi-billion dollar market" over the next few years. The analyst thinks the company can post 50% annual sales growth through 2021.
News For SILK From the Last 2 Days
There are no results for your query SILK
